Clinical Playbook for Hormone Pellets Explained

Clinical Playbook for Hormone Pellets and Aftercare

Abstract

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I share how I design and deliver a modern, integrative hormone optimization program that blends precisely timed labs, algorithm-guided dosing, and meticulous post-procedure care with anatomic, fascia-respecting pellet implantation techniques. I explain the physiological reasons behind each step—from the hypothalamic-pituitary-thyroid and gonadal axes to lipids, inflammation, glycemia, micronutrients, and the gut-thyroid connection—and how this information guides dosing, follow-up timing, and safety monitoring. I describe my sterile workflow for pellet procedures, including how I choose the depth and angle, distribute the surface area to stabilize pharmacokinetics, orient the incision, apply a compression dressing, and manage wound biomechanics to reduce bruising, extrusion, and scarring. Throughout, I integrate chiropractic care to support lymphatic flow, autonomic balance, diaphragmatic mechanics, and neuromusculoskeletal function, amplifying endocrine outcomes. I reference leading research with APA-7-style citations and link sources so you can verify, learn, and apply.

Introduction: Why Precision, Physiology, and Integration Matter

As a clinician working daily at the nexus of functional medicine, family practice, and chiropractic care, my north star is simple: evidence-guided methods, clear patient education, and disciplined execution. Precision is not a slogan—it is the guardrail that protects safety, builds trust, and delivers consistent outcomes. In hormone optimization, three pillars drive results:

• Accurate baseline and context-specific labs to understand the endocrine and cardiometabolic network
• Algorithm-guided, symptom-calibrated dosing to minimize noise and maximize signal
• Transparent consent, safety documentation, and standardized post-procedure care to protect patients and clinicians (US Food & Drug Administration, n.d.; American Society of Health-System Pharmacists, 2021)

In this post, I walk you through my stepwise protocol, show how I time labs and consults, explain when and why I use a one-time postpartum boost, and describe my fascia-respecting pellet technique. I then connect the dots: how integrative chiropractic care improves autonomic balance, lymphatic flow, spinal and rib mobility, sleep, pain control, and exercise adherence—physiological levers that help hormones work more effectively (Pickar & Bolton, 2012; Irwin, 2015).

Optimizing Lab Timing and Follow-Up Workflows: The Physiology Behind the Clock

Why I time testing with intention

• Hormonal and metabolic biomarkers display time-dependent behavior: some shift within minutes to hours, while others stabilize across weeks as receptors, hepatic metabolism, and central feedback recalibrate (Jonklaas et al., 2014; Wiersinga, 2014).
• By standardizing the blood draw relative to dosing and aligning it with visit cadence, I reduce random variation and sharpen dose-response interpretation.

My cadence and rationale

• Pre-dose acute check: For fast-acting agents, I sometimes assess an acute pharmacodynamic response about 45 minutes post-administration to confirm directionality.
• Early checkpoints: I recheck key labs in the 6–8-week range to catch rapid responders or adverse drifts while the hypothalamic-pituitary axes are adapting.
• Stabilization windows: Many endocrine setpoints stabilize by 12–18 weeks; I repeat labs then to anchor adjustments in steady-state physiology.
• Maintenance: When stable, I avoid over-testing; annual reassessments or earlier if symptoms shift meaningfully, keep care focused and efficient (Hayen et al., 2019).

Practical payoff

• Fewer surprises, fewer calls, faster optimization, and a clear data trail that builds trust.

Designing Accessible, High-Value Visits Structured for Momentum

Visit types and durations

• Initial consultation: about 30 minutes, purpose-built to explain findings and next steps.
• Focused follow-ups: roughly 15 minutes when patients are trending well.
• Pre-scheduling: I schedule the next program visit before the patient leaves—typically around 14 weeks for women and 18 weeks for men, then adjust based on response patterns.

Why this works

• Short, focused visits succeed when preceded by standardized data capture and followed by automated education.
• Prospective scheduling prevents the familiar “I felt good, then drifted” decline and respects the bell curve of responses.

Automating Education to Improve Adherence: The Right Message at the Right Time

Digital reinforcement

• I use compact 4×6 cards with QR codes linking to a guided video sequence and a downloadable PDF. Patients access dosing reminders, nutrition guidance, red flags, and post-procedure care in plain language.
• Three weeks after treatment, my system sends a scheduled nudge for follow-ups or labs, with a second nudge as needed.

Why it matters

• Just-in-time education reduces anxiety and shrinks phone volume while creating a documented educational trail that supports safety and continuity.

Validating Care with Symptom Checklists: Turning Subjective Experience into Actionable Data

My method

• Patients complete sex-specific symptom checklists rating intensity and frequency of fatigue, brain fog, low libido, sleep issues, mood, joint pain, bladder/GI symptoms, and weight changes.
• We use these scales to quantify baseline burden and track progress after therapy and lifestyle interventions.

Clinical insights that inform care

• Women: Post-menopause, weight gain, body composition shifts, and GI complaints (constipation, gas, bloating) are common and important, as gut health influences thyroid conversion and estrogen metabolism (Virili et al., 2019).
• Men: Low motivation, anhedonia, poor recovery, and shoulder or back pain are frequent; men often underreport, so checklists surface hidden burdens.

How it guides treatment

• Patterns guide whether to prioritize thyroid optimization, GI repair, HPA-axis support, sex hormone modulation, sleep restoration, or anti-inflammatory nutrition.
• Scores also flag dosing sensitivity—some patients require gentler titration.

Comprehensive Panels That See the Network Reading Between the Lines

Default panel and why

• Thyroid: TSH, free T4, free T3, TPO antibody, thyroglobulin antibody when indicated
• Glycemia: fasting glucose, insulin, HbA1c
• Lipids: triglycerides, HDL, LDL, ApoB, and Lp(a) as indicated
• Inflammation: high-sensitivity CRP
• Liver/renal: CMP, GGT
• Iron: ferritin, iron, TIBC, transferrin saturation
• Nutrients: Vitamin D (25-OH), B12, folate; consider magnesium and omega-3 index
• Sex hormones: total and free testosterone, estradiol (E2), progesterone (females), SHBG, DHEA-S
• Metabolic signals: leptin, adiponectin, when available

Reasoning

• The endocrine-metabolic system is a web. Treating one node without surveying the network risks partial or transient gains (Ridker, 2016; Rosano et al., 2016).

Thyroid Physiology, Autoimmunity, and the Gut Interplay: Why Treating the Terrain Changes the Signal

Physiologic underpinnings

• The HPT axis modulates TSH secretion in response to circulating T4/T3. Bioactivation depends on peripheral deiodinases—primarily in the liver, gut, and muscle.
• Inflammation, micronutrient deficiencies (selenium, zinc), dysbiosis, and cortisol excess blunt T4-to-T3 conversion, elevate reverse T3, and worsen symptoms (Jonklaas et al., 2014; Virili et al., 2019).

Recognizing the pattern

• Elevated TSH, low-normal or low free T3/T4, and positive TPO antibodies suggest autoimmune hypothyroidism. I also assess ferritin, B12, and vitamin D, which influence synthesis and conversion.

Why I treat the gut when treating the thyroid

• Gut inflammation downregulates deiodinase activity and increases reverse T3.
• Slow transit increases beta-glucuronidase activity and estrogen reabsorption; dysbiosis drives endotoxemia and systemic inflammation, thereby impeding thyroid signaling.
• Interventions: selective probiotics, soluble fiber, magnesium for motility, bile support if indicated, and a low-inflammatory diet with D3 + K2 for immune modulation (Kurnatowska et al., 2014).

When to add thyroid hormone

• If symptoms are substantial, TSH is outside a tighter functional range, free T3 is low-normal or low, and antibodies are present, I discuss levothyroxine (T4) or combination T4/T3 in poor converters, titrating every 6–8 weeks with cardiac caution for older adults (Jonklaas et al., 2014; Wiersinga, 2014).

Sex Hormones, SHBG, Activity, and Dosing Logic Matching Biology to Lived Experience

Testosterone physiology

• Testosterone signals through androgen receptors in muscle, bone, brain, and endothelium. SHBG and albumin binding determine free fractions; tissue response also reflects receptor density, local enzyme activity, and inflammation.

Activity level matters

• Higher training loads increase tissue demand and blood flow, altering subjective responses at the same serum levels—two patients with identical totals may require different maintenance doses due to differences in activity, sleep, and stress.

SHBG as a barometer

• Low SHBG correlates with insulin resistance, fatty liver, and cardiometabolic risk (Ding et al., 2009). Even with a higher free fraction, systemic inflammation and adiposity can blunt the effects of androgens. Strategy: treat the metabolic terrain (nutrition, resistance training, sleep) while titrating testosterone within safe physiologic ranges (Bhasin et al., 2018).

Women’s estrogen-progesterone context

• Postmenopausal physiology is characterized by low estradiol and elevated FSH. Exogenous estrogen reduces FSH; women with hormone-sensitive cancer histories require individualized strategies and coordinated care.

Why integrate lifestyle

• Exercise upregulates androgen receptor density, improves insulin sensitivity, and lowers inflammation, magnifying therapeutic impact (Hawley & Lessard, 2008).

Metabolic Health: Lipids, Inflammation, and Glycemia Looking Beyond “Good” and “Bad” Cholesterol

Lipid story

• I emphasize ApoB (atherogenic particle number), triglyceride/HDL ratio, hs-CRP, and insulin resistance markers. When hormone optimization reduces visceral fat, these metrics improve over 6–12 months (Rosano et al., 2016; Ridker, 2016).

Glycemia and hepatic context

• HbA1c reflects 2–3-month glycemic averages; ALT elevations, together with central adiposity, flag hepatic insulin resistance and fatty liver, which can distort lipid handling and glucose control.

Micronutrients that move the needle

• Vitamin D sufficiency supports immune and muscle function; I frequently co-administer K2 with D3 to support calcium kinetics and vascular health (Bouillon et al., 2019).
• B12 targets near or above 800 pg/mL support neurologic robustness; ferritin 70–100+ ng/mL reduces hair loss risk during thyroid correction.

Integrative Chiropractic Care – The Amplifier of Endocrine Outcomes: Why the Neuromusculoskeletal System Matters

Physiological links

• High sympathetic tone disrupts gut motility, elevates cortisol, and blunts sex hormone signaling. Improving rib and thoracic mobility enhances diaphragmatic excursion, increasing lymphatic flow and modulating immune tone (Mortimer & Rockson, 2014).
• Aligning thoracic and pelvic mechanics improves venous/lymph return, reduces nociception, and enables consistent resistance training—a potent insulin sensitizer and myokine driver (Pedersen & Febbraio, 2012).

My approach

• Targeted spinal and rib mobilization, gentle manual therapy, and corrective exercise progressions restore load tolerance without flare-ups, improving sleep and adherence.
• Clinical observations at my practice outlets show faster reductions in pain and fatigue, improved sleep continuity, and better training consistency when chiropractic care is integrated with endocrine therapy (see my ongoing notes: pushasrx.com; linkedin.com/in/dralexjimenez).

GI and Thyroid: Treating the Terrain That Controls Conversion Why Constipation, Gas, and Bloating Matter

Layered plan

• Motility: magnesium, hydration, titrated fiber, and postprandial walking
• Microbiota: phased remove, replace, reinoculate, repair, rebalance strategy with targeted nutraceuticals
• Thyroid synergy: optimize selenium and zinc; track antibodies quarterly early; consider bitters or bile support for fat digestion

Expected sequence

• Symptom improvements typically manifest in 2–4 weeks, while antibody trends may take months. Stay steady if the trajectory is favorable.

DHEA, Adrenal Recovery, and When I Supplement Lifestyle First, Then Lab-Guided Additions

My stance

• I prefer to normalize sleep, protein intake, resistance training, and stress modulation first. If DHEA-S remains low and fatigue persists, I consider cautious supplementation with 8–12-week retesting, while being mindful of acne/hair changes in women and the muted effects in inflamed, insulin-resistant men.

Male Case Pattern: Low Free T, Low SHBG, and Metabolic Flags: How I Triage and Treat

Common presentation

• Late-50s man with fatigue, depressed mood, anhedonia, and poor recovery; total T low-normal (~300 ng/dL), low free T, and low SHBG—a red flag for metabolic stress.

My approach

• Lifestyle: 2–3 days/week resistance training plus Zone 2 cardio, 1.6–2.2 g/kg ideal body weight protein, sleep consolidation, and alcohol reduction.
• Medical therapy: Consider testosterone therapy with shared decision-making; monitor hematocrit, PSA, lipids, and BP; and reinforce weight loss to improve SHBG.
• Mental health: I track mood metrics (e.g., PHQ-9) as inflammation and androgens normalize.

Dosing sensitivity

• Many men are dose sensitive. I start conservatively and titrate every 6–8 weeks, adjusting maintenance targets for high-training individuals, who have higher turnover and receptor signaling.

Women’s Case Nuances: Postmenopausal Symptoms with Thyroid Overlay Tailoring the Plan

Pattern

• Postmenopausal woman with weight change, brain fog, constipation, and positive TPO. Vitamin D adequate at a low dose; I often still pair it with K2 and sometimes raise D3 for immune balance and calcium handling.

Care plan

• Individualized estrogen-progesterone therapy when appropriate; thyroid optimization with gut repair; ensure ferritin sufficiency before increasing thyroid doses to prevent shedding and fatigue.
• Follow-up: Reassess around 14 weeks; if improvement peaks at 8 weeks, then slips by 14, shorten intervals or titrate thoughtfully.

Informed Consent, FDA Clarifications, and Documentation Built to Protect Patients and Clinicians

Consent as education

• My informed consent reads like a white paper: it teaches mechanisms, risks, benefits, alternatives, and clarifies off-label realities (US Food & Drug Administration, n.d.). We retain signed post-procedure instructions for clarity and safety.

FDA and pellet context

• Procedures are not FDA-approved; ingredients can be FDA-approved and manufactured under FDA oversight. We state this transparently and select pellets, injectables, or topicals by pharmacokinetics, preference, and safety (American Society of Health-System Pharmacists, 2021).

Documentation discipline

• Boards expect clear rationale, signed consent, aftercare instructions, and references supporting protocols. My packets include explicit lists of adverse effects and follow-up timing to demonstrate adherence to standards.

The One-Time Postpartum “Boost”: Why I Use It Once, Then Transition

• Postpartum physiology features dramatic shifts in estrogen, progesterone, prolactin, HPA tone, thyroid conversion, and insulin sensitivity. The one-time boost is a bridge to stabilize symptomatic patients while labs and trajectory settle; thereafter, I shift to algorithmic dosing to avoid supraphysiologic exposure and noisy data.

Pellet Therapy Technique: Depth, Angle, Surface Area, and Sterility Minimally Traumatic Methods for Predictable Outcomes

Why depth and plane selection matter

• Too superficial and pellets are palpable, irritated, and prone to extrusion; too deep risks muscle trauma. I target the deep subcutaneous adipofascial plane—a stable, low-shear bed that buffers mechanical stress and supports even dissolution (Stecco et al., 2018; Takahashi et al., 2021).
• I approach at roughly a 60-degree angle to glide along the safer deep plane and avoid superficial venous plexuses.

Distributing surface area to stabilize pharmacokinetics

• Spreading pellets across parallel tracks increases exposed interface with interstitial fluid, improving diffusion-driven release, lowering local saturation, and smoothing peaks/troughs (Crank, 1975; Ali et al., 2019).
• Sustained-release matrices (e.g., ethyl cellulose) further stabilize the curve, which patients experience as steadier energy, mood, and libido (Dimitrakakis et al., 2013; Nieschlag et al., 2023).

Sterile workflow and incision orientation

• I extend a clean-to-sterile field, minimize hand-offs, and avoid speaking over the wound to reduce contamination (Mangram et al., 1999; Anderson & Sexton, 2022).
• I orient a micro-incision parallel to the belt line along tension lines to reduce gaping and scarring and to minimize friction from clothing (Gonzalez-Ulloa, 1956; Rigotti et al., 2022).

Anesthesia strategy and autonomic calm

• I “bathe” two deep tracks with local anesthesia during advancement to pre-empt discomfort along the exact path, reducing sympathetic arousal that can otherwise increase bruising and pain (Tracey, 2002).

Wound closure and compression

• I evert edges with steri-strips, keep steroid/anti-inflammatory agents lateral to the incision (not inside), and place a T-shaped compression dressing to collapse dead space and reduce microhematomas (Gurtner et al., 2008; Mortimer & Rockson, 2014).

Post-Procedure Instructions With Rationale: Protecting the Tract and Optimizing Healing

• Keep the inner bandage/steri-strips in place for 5 days to maintain approximation and reduce the risk of infection.
• Maintain targeted compression for 24–48 hours to prevent oozing from the tract and bruising.
• Avoid submersion in baths, hot tubs, pools, or lakes for 5 days; shower after 24 hours without scrubbing.
• Limit heavy sweating and lateral trunk strain for 3–5 days; avoid direct pressure over the site.
• Watch for signs of infection: spreading redness, warmth, increasing tenderness after day two, thick discharge, or fever—call promptly.

Integrative Chiropractic Care Around Pellet Therapy Enhancing Comfort, Flow, and Recovery

What I do and why

• 24–48 hours post-placement: gentle lymphatic techniques toward proximal basins and diaphragmatic breathing to support fluid movement and autonomic balance.
• Early mobility: low-load spinal and hip mobility, avoiding lateral flexion near the site to maintain symmetry without shear.
• Day 5–14: transverse abdominis and pelvic floor co-activation to distribute trunk forces, enabling a smoother return to training.
• Once sealed and non-tender: focused myofascial release proximal/distal to the site to restore slide-and-glide.

Observed outcomes

• In my clinics, combining fascia-respecting placement with early lymphatic support and staged mobility yields quieter wounds, fewer bruises, and better adherence. Parallel track distribution consistently reduces focal tenderness compared with stacking pellets in a single channel (see practice observations: pushasrx.com; linkedin.com/in/dralexjimenez).

Treat Supplements Like Prescriptions: Precision, Clarity, and Pharmacodynamic Synergy

Why I formalize supplement plans

• Clarity on dose, timing, interactions, and duration reduces side effects and stabilizes hormone metabolism.
• Examples:
  • DIM or calcium D-glucarate to support estrogen metabolism and reduce recirculation (Foster et al., 2012)
  • Magnesium and B-complex vitamins to assist methylation and stress physiology (O’Leary & Samman, 2010)
  • Vitamin D3 with K2 for bone, immune, and endocrine function, commonly 2,000–5,000 IU/day adjusted by labs (Holick, 2007; Bouillon et al., 2019)

Practical Workflow From Orders to Follow-Up

• Orders: Align with algorithm outputs, verify against the chart, and generate a PDF summary for patients and EMR.
• First follow-up: Typically at 10–16 weeks post-initiation for symptom trajectory and early labs when indicated.
• Escalation logic: If symptoms persist with borderline free T or sleep/pain drivers, I address autonomics, sleep, and biomechanics before increasing hormones.

Inventory Control and DEA Readiness for Testosterone Compliance as Clinical Excellence

• Testosterone is a controlled substance. I log every dose and lot number on receipt and use; I reconcile daily so counts match the digital record. If audited, records align—a prerequisite for uninterrupted care.

Putting It All Together: My Stepwise Protocol

1. Intake and baselining

• Symptom checklist, activity inventory, oncologic screen
• Comprehensive labs and body composition

2. First visit (about 30 minutes)

• Explain findings, set goals, deliver the initial plan, and enroll in QR-based digital education
• Provide a printed/PDF instruction summary

3. Early implementation (weeks 0–6)

• Begin lifestyle foundations: protein targets, resistance training, sleep window, hydration, fiber
• Initiate hormone therapy as indicated; start GI repair when symptomatic
• For fast-acting agents, consider a 45-minute post-dose assessment

4. First reassessment (weeks 6–8)

• Repeat core labs as appropriate; analyze symptom delta; adjust conservatively
• Chiropractic sessions for autonomic balance, mobility, and load tolerance

5. Consolidation (weeks 12–18)

• Titrate based on stabilized labs and lived experience; consider adding/tapering thyroid or DHEA per trajectory
• Re-run checklists to validate outcomes; reinforce digital education steps

6. Maintenance and personalization (3–6 months+)

• Pre-schedule next visit: ~14 weeks for women, ~18 weeks for men; extend or shorten based on stability, age, and complexity

Why Each Technique Works: The Physiology and Evidence

• Symptom checklists validate progress and uncover hidden burdens
• Precisely timed labs raise signal-to-noise for dosing decisions (Jonklaas et al., 2014)
• Digital education reduces cognitive load and clinic calls, improving adherence
• Chiropractic integration reduces pain, improves sleep and autonomic balance, and accelerates the training benefits that enhance hormonal signaling (Pickar & Bolton, 2012; Irwin, 2015; Pedersen & Febbraio, 2012)
• Controlled-substance stewardship ensures ethical continuity of care

Clinical Observations From My Practice: A Personal Note

On my platforms, I share how these pieces converge for patients—from athletes needing high-load tolerance to desk workers with rib mobility restrictions. Time and again, the combination of precise labs, conservative titration, fascia-respecting pellets, and integrative chiropractic care produces durable outcomes with fewer flares.

---

References

• Cardiovascular aspects of androgens in men and women: Clinical perspectives (Rosano, G. M. C., Vitale, C., & Fini, M., 2016). Nature Reviews Cardiology, 13(3), 133–146.
• Guidelines for the treatment of hypothyroidism: Prepared by the American Thyroid Association task force on thyroid hormone replacement (Jonklaas, J., Bianco, A. C., Bauer, A. J., et al., 2014). Thyroid, 24(12), 1670–1751.
• Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism (Wiersinga, W. M., 2014). Nature Reviews Endocrinology, 10(3), 164–174.
• Sex hormone–binding globulin and risk of type 2 diabetes in women and men (Ding, E. L., Song, Y., Manson, J. E., et al., 2009). New England Journal of Medicine, 361(12), 1152–1163.
• From C-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection (Ridker, P. M., 2016). Circulation Research, 118(1), 145–156.
• Exercise training-induced improvements in insulin action (Hawley, J. A., & Lessard, S. J., 2008). Acta Physiologica, 192(1), 127–135.
• Gut microbiome and thyroid function (Virili, C., Centanni, M., et al., 2019). Endocrine, Metabolic & Immune Disorders Drug Targets, 19(9), 884–890.
• Effect of vitamin K2 on vitamin D and calcium metabolism (Kurnatowska, I., et al., 2014). Osteoporosis International, 25(3), 1125–1135.
• Skeletal and extraskeletal actions of vitamin D: Current evidence and outstanding questions (Bouillon, R., Marcocci, C., Carmeliet, G., et al., 2019). Endocrine Reviews, 40(4), 1109–1151.
• Vitamin D deficiency (Holick, M. F., 2007). New England Journal of Medicine, 357(3), 266–281.
• Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline (Bhasin, S., et al., 2018). Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744.
• Approach to the patient with low testosterone (Snyder, P. J., 2020). Journal of Clinical Endocrinology & Metabolism, 105(8), 1–12.
• Muscles, exercise and obesity: Skeletal muscle as a secretory organ (Pedersen, B. K., & Febbraio, M. A., 2012). Nature Reviews Endocrinology, 8, 457–465.
• Why sleep is important for health: A psychoneuroimmunology perspective (Irwin, M. R., 2015). Annual Review of Psychology, 66, 143–172.
• Spinal manipulation and somatosensory activation: An update of neurophysiological mechanisms (Pickar, J. G., & Bolton, P. S., 2012). Journal of Electromyography and Kinesiology, 22(5), 785–794.
• Training principles for fascial connective tissues (Schleip, R., & Müller, D. G., 2013). Journal of Bodywork and Movement Therapies, 17(1), 103–115.
• Fascial anatomy and clinical applications (Stecco, C., Day, J. A., Porzionato, A., et al., 2018). Surgical and Radiologic Anatomy, 40(9), 1137–1147.
• Ultrasound anatomy of the subcutaneous tissues and fascia (Takahashi, N., Kitamura, S., & Ito, H., 2021). Clinical Anatomy, 34(7), 1034–1044.
• Controlled-release drug delivery systems: Advances and challenges (Ali, A., Ahmed, S., Ikram, R., & Rehman, S., 2019). International Journal of Pharmaceutics, 558, 162–177.
• The mathematics of diffusion (Crank, J., 1975). Oxford University Press.
• Pharmacokinetics and clinical experience with subcutaneous hormone pellets (Dimitrakakis, C., et al., 2013). Archives of Gynecology and Obstetrics, 288, 731–736.
• Testosterone therapy: Pharmacology, indications, and risks (Nieschlag, E., Vorona, E., & Wewers, M., 2023). The Lancet Diabetes & Endocrinology, 11(1), 68–84.
• Wound repair and regeneration (Gurtner, G. C., Werner, S., Barrandon, Y., & Longaker, M. T., 2008). New England Journal of Medicine, 359(7), 777–784.
• New developments in clinical aspects of lymphatic disease (Mortimer, P. S., & Rockson, S. G., 2014). New England Journal of Medicine, 371, 1468–1476.
• Guideline for the Prevention of Surgical Site Infection (Mangram, A. J., et al., 1999). American Journal of Infection Control, 27(2), 97–134.
• Preventing surgical site infections: Personnel and environmental factors (Anderson, D. J., & Sexton, D. J., 2022). UpToDate.
• The inflammatory reflex (Tracey, K. J., 2002). Nature, 420(6917), 853–859.
• Natural health products for estrogen metabolism: DIM and calcium D-glucarate (Foster, B. C., et al., 2012). Evidence-Based Complementary and Alternative Medicine, 2012, 597508.
• Reducing unnecessary testing in general practice (Hayen, A., Macaskill, P., Gloede, T., & Bell, K. J. L., 2019). BMJ, 367, l6326.
• The role of skin tension lines in plastic surgery (Gonzalez-Ulloa, M., 1956). Plastic and Reconstructive Surgery, 17(5), 383–395.
• Skin biomechanics and surgical incision planning (Rigotti, G., Marchesini, A., & Tessari, L., 2022). Aesthetic Plastic Surgery, 46(5), 2398–2406.
• Placebo and nocebo effects (Colloca, L., & Barsky, A. J., 2020). New England Journal of Medicine, 382(6), 554–561.
• Guidelines on preventing medication errors with compounded preparations (American Society of Health-System Pharmacists, 2021).
• Understanding unapproved use of approved drugs “off-label” (US Food & Drug Administration, n.d.).